嘉化能源董事長管建忠:加碼技術創新 力爭磺化醫藥分拆上市科創板
嘉化能源近期發佈的2019年半年報顯示,公司磺化醫藥業務出現爆發式增長,實現銷售收入約4.11億元,同比增幅達87.87%。數據顯示,從2013年到2018年,嘉化能源磺化醫藥系列產品毛利率由41.56%穩步提升至60.07%,年均增長率超過50% 。嘉化能源董事長管建忠對《科創板日報》表示,公司磺化醫藥業務技術處於行業前沿,也不存在同業競爭和關聯交易,符合科創板企業申報條件。在分拆上市政策細則落定後,希望能儘快趕在第一批報備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.